Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma [bulk RNA-seq]

ABSTRACT: T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma [bulk RNA-seq]

PROVIDER: PRJNA772733 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma

Project description:T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma

| PRJNA772729 | ENA

T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma [bulk RNA-seq]

Project description:Severe immune-related adverse events (irAEs) occur in up to 60% of melanoma patients treated with immune checkpoint inhibitors (ICIs). However, it remains unknown whether a common baseline immunological state precedes irAE development. Leveraging CyTOF, single-cell RNA sequencing, bulk RNA sequencing, and T cell receptor sequencing to analyze pretreatment blood from metastatic melanoma patients treated with ICIs, we investigated cellular factors associated with severe irAE development regardless of organ system involvement. Our results demonstrate circulating T cell characteristics associated with ICI-induced toxicity, with implications for improved diagnostics and clinical management.

2022-01-13 | GSE186143 | GEO

T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma [scRNA-Seq]

Project description:T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma [scRNA-Seq]

| PRJNA781606 | ENA

T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma [scRNA-Seq]

2022-01-13 | GSE189125 | GEO

T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma [BCR and TCR scRNA-Seq]

2022-01-13 | GSE189126 | GEO

T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma [BCR and TCR scRNA-Seq]

Project description:T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma [BCR and TCR scRNA-Seq]

| PRJNA781605 | ENA

Melanoma Sequential Immune Checkpoint Blockade Treatment Sequencing Study

Project description:Melanoma Sequential Immune Checkpoint Blockade Treatment Sequencing Study

| PRJNA397812 | ENA

Molecular patterns of resistance to immune checkpoint blockade in melanoma [NanoString GeoMx]

Project description:Tumor cell-containing Regions of Interest from 17 patients with melanoma after progression to Immune Checkpoint Blockade were profiled at the transcriptomic level.

2024-03-12 | GSE261347 | GEO

Altered expression profile of multiple tissues after immune checkpoint blockade treatment

Project description:We report the expression alteration of kidney, lung, liver, heart, skeletal muscle and tumor with high dosage of immune checkpoint blockade (ICB) or IgG treatment in C57BL/6 mice bearing MC38 tumor. We find several differentially expressed genes after ICB treatment in different tissues as compared with IgG control group. This study provides a basis for the ICB induced toxicity.

2022-12-02 | GSE145573 | GEO

T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma.

Project description:Severe immune-related adverse events (irAEs) occur in up to 60% of patients with melanoma treated with immune checkpoint inhibitors (ICIs). However, it is unknown whether a common baseline immunological state precedes irAE development. Here we applied mass cytometry by time of flight, single-cell RNA sequencing, single-cell V(D)J sequencing, bulk RNA sequencing and bulk T cell receptor (TCR) sequencing to study peripheral blood samples from patients with melanoma treated with anti-PD-1 monotherapy or anti-PD-1 and anti-CTLA-4 combination ICIs. By analyzing 93 pre- and early on-ICI blood samples and 3 patient cohorts (n = 27, 26 and 18), we found that 2 pretreatment factors in circulation-activated CD4 memory T cell abundance and TCR diversity-are associated with severe irAE development regardless of organ system involvement. We also explored on-treatment changes in TCR clonality among patients receiving combination therapy and linked our findings to the severity and timing of irAE onset. These results demonstrate circulating T cell characteristics associated with ICI-induced toxicity, with implications for improved diagnostics and clinical management.

| S-EPMC8866214 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data